Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/08/2026 14:17 PDT] Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), Up By 100% ($2.6) From $2.6 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/06/2026 07:02 PDT] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [05/04/2026 06:54 PDT] BDTX Expected to Trade Up After Bullish Patterns Develop
• [04/24/2026 04:24 PDT] BDTX Expected to Trade Up After Bullish Patterns Develop
• [04/22/2026 09:51 PDT] Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), Up By 100% ($2.85) From $2.85 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/22/2026 09:51 PDT] Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), Up By 100% ($2.66) From $2.66 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/17/2026 10:30 PDT] Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), Up By 100% ($2.5) From $2.5 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/16/2026 10:30 PDT] Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), Up By 100% ($2.33) From $2.33 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/16/2026 06:23 PDT] BDTX Expected to Trade Up Short Term
• [04/15/2026 07:21 PDT] BDTX Expected to Trade Up After Bullish Patterns Develop
• [04/08/2026 07:16 PDT] BDTX Expected to Trade Down After Bearish Patterns Develop
• [04/07/2026 07:12 PDT] BDTX Expected to Trade Up After Bullish Patterns Develop
• [04/02/2026 07:24 PDT] BDTX Expected to Trade Up After Bullish Patterns Develop
• [03/31/2026 06:50 PDT] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.